ArticleAnnals of clinical and translational neurology2026
Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo evaluate whether add-on memantine would exacerbate seizures in people with epilepsy.
methodsThis was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks. Participants were required to be adherent to their antiseizure medication regimens, which had remained unchanged for at least 24 weeks before recruitment. Participants were prescribed memantine and categorized according to their treatment decisions (memantine group vs. non-memantine group). Primary outcome measures were the occurrence of new-onset bilateral tonic-clonic seizure, new-onset status epilepticus, and increased seizure frequency (≥ 25%). The incidence of other adverse events (AEs) and 24-week retention rate were secondary outcome measures.
resultsTwo hundred and eleven participants were enrolled (median age, 63; male, 65%). Among them, one hundred and one (48%) started memantine. Baseline seizure characteristics were comparable between the two groups. During follow-up, no new-onset bilateral tonic-clonic seizure was recorded; there was one status epilepticus in the non-memantine group. Increased seizure frequency was reported by 12 (6%) participants (memantine vs. non-memantine, seven vs. five). Other AEs in the memantine group included headache (7%), dizziness (5%), fatigue (4%), drowsiness (2%), and anorexia (2%). The 24-week retention rate was 91%.
interpretationAdjunctive memantine was well tolerated in people with epilepsy regarding seizure control and other AEs. Previous warnings might have been disproportionate. Large-scale, randomized trials are required to confirm this and further elucidate its efficacy profiles in epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.